AusBiotech and BIO co-hosted 'Investing in Australia' roundtable brought Australian BIO delegates together with global leaders to enablement opportunities for trade and investment in Australia.
The roundtable included the Hon. Ed Husic, Minister for Industry and Science, a cross-section of AusBiotech members representing the life sciences value chain, global companies, government representatives, and potential future investors to explore how the different parts of our sector can work together with intention to continue building Australia's thriving life sciences ecosystem.
Led by Rebekah Cassidy, CEO, AusBiotech, and Justin Pine, Senior Director International Affairs, Biotechnology Innovation Organization (BIO), roundtable members discussed new opportunities to continue building expertise, skills and capability as Australian biotech scales up and out. Roundtable members also discussed new opportunities to foster partnership across the investor landscape and work together for the betterment of the biotechnology sector.
"It was a powerful discussion that offered a hothouse for new ideas and new ways to harness the momentum building behind Australian biotech. We're looking forward to continuing the conversation with our members, the broader life sciences community and government when we're back on home ground," Rebekah Cassidy said.
Thank you to the Hon. Ed Husic MP and representatives from Acadia Pharmaceuticals, Argenica, AdAlta, Amgen Inc., Attentive Science, BeiGene, BioCina, Bristol Myers Squibb, CMAX, CSIRO, CSL, Cytiva, Dimerix, Eli Lilly, Gingko Bioworks, Illumina, Medicines Australia, Merck, Millipore Sigma Corporation, MTPConnect, Myeloid Therapeutics, Novartis, Novo Cina, Noxopharm, Nucleus Network, Opthea, Resolian, Sanofi, Southern Star, Vaxxas, and Viatris, for their engagement during the 'Investing in Australia' roundtable.
This year's Team Australia delegation state representatives, AusBiotech, MTPConnect, hundreds of Australian companies, and delegates and more all standing united to shine a light on Australia's burgeoning life science ecosystem.
Taking place in San Diego from 3-6 June and hosted by BIO, the BIO International Convention is the most influential event in the global life sciences calendar. This year's conference is expected to draw more than 20,000 biotech and pharma leaders from 7,000 companies and 84 countries.
AusBiotech's mission to BIO includes showcasing Australia's capabilities and capacity at the International Council of Biotechnology Associations (ICBA), hosting the global roundtable in partnership with the BIO and the Hon. Ed Husic MP on Investing in Australia, and showcasing the Australian delegation through 'Access Australia', an online platform that enables easy searching of and connection with the Australian delegation attending BIO 2024 – ensuring easier and quicker business development opportunities for our members during this global life science event.
Australia's mission to the world's largest life sciences convention continues to grow year-on-year, highlighting the industry's commitment to fostering global collaborations and partnerships in key markets.
AusBiotech's commitment to members at BIO is part of its global strategy to facilitate international opportunities for investment, collaborations and partnerships.
AusBiotech is committed to supporting these ongoing opportunities for industry, which are crucial for the growth of the Australian life sciences sector, and, ultimately for continuing Australia's position in the sector globally.
AusBiotech is proudly working in partnership with MTPConnect, Austrade, CSIRO and state governments: New South Wales Government, South Australian Government, Victorian Government, Queensland Government, and Western Australian Government, to drive a united 'Team Australia' approach that supports the whole ecosystem.
